Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Cytosine-arabinoside stimulates the capability of human marrow stromal cells to support normal hematopoiesis.

Li H, Koh KR, Toramoto T, Nakamae H, Yamane T, Ohta K, Hino M.

Osaka City Med J. 2010 Dec;56(2):11-20.

PMID:
21466125
2.

Interactions between acute lymphoblastic leukemia and bone marrow stromal cells influence response to therapy.

Tesfai Y, Ford J, Carter KW, Firth MJ, O'Leary RA, Gottardo NG, Cole C, Kees UR.

Leuk Res. 2012 Mar;36(3):299-306. doi: 10.1016/j.leukres.2011.08.001. Epub 2011 Sep 1.

PMID:
21889797
3.

Bone marrow stromal dysfunction in mice administered cytosine arabinoside.

Ben-Ishay Z, Barak V.

Eur J Haematol. 2001 Apr;66(4):230-7.

PMID:
11380602
6.
7.
8.

Expression of MDR1 by normal bone marrow cells and its implication for leukemic hematopoiesis.

Drach J, Zhao S, Drach D, Körbling M, Engel H, Andreeff M.

Leuk Lymphoma. 1995 Feb;16(5-6):419-24. Review.

PMID:
7540457
9.

Resistance to cytosine arabinoside by retrovirally mediated gene transfer of human cytidine deaminase into murine fibroblast and hematopoietic cells.

Momparler RL, Eliopoulos N, Bovenzi V, Létourneau S, Greenbaum M, Cournoyer D.

Cancer Gene Ther. 1996 Sep-Oct;3(5):331-8.

PMID:
8894252
10.
11.

Prolonged exposure to cytosine arabinoside in the presence of hematopoietic growth factors preferentially kills leukemic versus normal clonogenic cells.

Van Der Lely N, De Witte T, Muus P, Raymakers R, Preijers F, Haanen C.

Exp Hematol. 1991 May;19(4):267-72.

PMID:
2055291
12.

[Mice transduced with double-mutant dihydrofolate reductase-cytidine deaminase fusion gene attained protection from high dose chemotherapy].

Lu P, Lu Y, Pang K, Wang SB, Chen JQ, Xu HM, Wang JK, Zhao SC.

Zhonghua Wai Ke Za Zhi. 2005 Aug 1;43(15):998-1001. Chinese.

PMID:
16194358
13.

[Enhanced sensitivity to cytosine arabinoside by combined stimulation of steel factor and GM-CSF in a factor-dependent leukemic cell line, MO7e--in terms of a possible clinical application to AML treatment].

Gotoh A, Kawanishi Y, Kurosawa K, Miyazawa K, Ohtaka M, Aizawa S, Kimura Y, Yoshikawa O, Toyama K.

Rinsho Ketsueki. 1993 Jul;34(7):821-8. Japanese.

PMID:
7689660
14.

Bone marrow connexin-43 expression is critical for hematopoietic regeneration after chemotherapy.

Presley CA, Lee AW, Kastl B, Igbinosa I, Yamada Y, Fishman GI, Gutstein DE, Cancelas JA.

Cell Commun Adhes. 2005 Jul-Dec;12(5-6):307-17.

PMID:
16531325
15.
16.

Imatinib mesylate selectively influences the cellular metabolism of cytarabine in BCR/ABL negative leukemia cell lines and normal CD34+ progenitor cells.

Bornhäuser M, Illmer T, Le Coutre P, Pursche J, von Bonin M, Freiberg-Richter J, Schaich M, Platzbecker U, Thiede C, Ottmann OG, Köhne Ch, Braess J, Ehninger G, Schleyer E.

Ann Hematol. 2004;83 Suppl 1:S61-4. Review.

PMID:
15124675
18.
19.

Post-chemotherapy and cytokine pretreated marrow stromal cell layers suppress hematopoiesis from normal donor CD34+ cells.

Schwartz GN, Warren MK, Rothwell SW, Zujewski J, Halverson DC, Cowan KH, Tolcher A, O'Shaughnessy J, Gress RE.

Bone Marrow Transplant. 1998 Sep;22(5):457-68.

20.

Bone marrow stromal cells and the upregulation of interleukin-8 production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the NF-kappaB and JNK/AP-1 pathways.

Scupoli MT, Donadelli M, Cioffi F, Rossi M, Perbellini O, Malpeli G, Corbioli S, Vinante F, Krampera M, Palmieri M, Scarpa A, Ariola C, Foà R, Pizzolo G.

Haematologica. 2008 Apr;93(4):524-32. doi: 10.3324/haematol.12098. Epub 2008 Mar 5.

Supplemental Content

Support Center